Rosen Comments on Benefits of More FDA-Approved Generic Drugs
31 January 2018
Health Care on Bloomberg Law
Partner David Rosen was quoted in a Health Care on Bloomberg Law article, “Critics Say Trump’s Drug Price Talk Empty without Actions,” about the FDA approving a record number of generic drugs in 2017 amid speculation that President Trump doesn’t want to lower prescription drug prices.
Rosen said it’s encouraging that drug pricing and generic drugs are on Trump’s mind. He explained that generic drugs “can certainly hold down health-care costs” by giving people access to products that are high quality, therapeutically equivalent and lower cost, and that FDA Commissioner Scott Gottlieb is working to make generic drugs more accessible and to ensure applications are approved in a timely manner.
Rosen said it’s encouraging that drug pricing and generic drugs are on Trump’s mind. He explained that generic drugs “can certainly hold down health-care costs” by giving people access to products that are high quality, therapeutically equivalent and lower cost, and that FDA Commissioner Scott Gottlieb is working to make generic drugs more accessible and to ensure applications are approved in a timely manner.
People
Related News
27 August 2024
In the News
Samuel Goldstick Assesses Data Privacy Challenges for Automakers
Foley & Lardner LLP partner Samuel Goldstick underscored how disclosure can help automakers reduce legal risk in the Automotive Dive article, "Automakers face growing data privacy challenges, experts say."
26 August 2024
In the News
Judith Waltz Quoted on Inflation Reduction Act, Pharma Impact
Foley & Lardner LLP partner Judith Waltz is quoted in the PharmaVoice article, "Pharmas’ IRA court losses mount. They keep pursuing them."
20 August 2024
In the News
Kevin Hyde Featured in Q&A on Jacksonville Legal Market – 'The outlook is good'
Foley & Lardner LLP partner Kevin Hyde is featured in a Capital Analytics Associates Q&A on the major achievements of Foley's Jacksonville office, key trends in the legal market, and the firm's commitment to its talent and client service.